Metastatic Melanoma, Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Conditions
Brief summary
This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Aldesleukin may stimulate the white blood cells to kill cancer. Ziv-aflibercept may stop the growth of melanoma by blocking blood flow to the tumor. It is not yet known whether aldesleukin is more effective with or without ziv-aflibercept in treating melanoma.
Detailed description
PRIMARY OBJECTIVES: I. Test the hypothesis that combination biotherapy with aflibercept (ziv-aflibercept) and high-dose (HD) interleukin (IL)-2 (aldesleukin) will improve the progression-free survival compared to HD IL-2 alone. SECONDARY OBJECTIVES: I. Evaluate the response rate (complete response \[CR\] + partial response \[PR\]) of aflibercept and HD IL-2 as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 and compare to results of HD IL-2 alone. II. Evaluate the toxicities and tolerance of combination biotherapy with aflibercept and HD IL-2 and maintenance aflibercept alone in this patient population and compare to HD-IL2 alone. III. Test the hypotheses related to the laboratory correlative studies. IV. Evaluate the overall survival of patients treated with aflibercept and HD IL-2 and HD IL-2 alone. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive ziv-aflibercept intravenously (IV) over at least 1 hour on day 1 of weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3-4 months for 5 years.
Interventions
BIOLOGICALAldesleukin
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALZiv-Aflibercept
Given IV
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
17 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed metastatic melanoma (includes American Joint Committee on Cancer \[AJCC\] stage IV or advanced/inoperable stage III; also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases) * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 10 mm with computed tomography (CT) scan or clinically (must be measurable with calipers) according to RECIST version 1.1 * Patients must be free of brain metastasis by contrast-enhanced CT/magnetic resonance imaging (MRI) scans within 4 weeks prior to enrollment; if known to have prior brain metastases, must not have evidence of active brain disease after definitive therapy (surgery, radiation therapy, or stereotactic radiosurgery) on two successive MRI evaluations at least 3 months apart (one of which is =\< 4 weeks prior to starting the study drugs) * A patient may be treatment naïve; however, up to two prior regimens for metastatic melanoma are allowed; prior adjuvant interferon (IFN)-alpha is allowed; no prior therapy with bevacizumab, aflibercept or interleukin-2 (IL-2) * Patients must not have received systemic therapy or radiotherapy within the preceding 4 weeks; patients must have recovered from adverse events due to agents administered more than 4 weeks earlier * Patients must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery, and be free of significant detectable infection * For patients who have received prior anti-cytotoxic T-lymphocyte antigen (CTLA)4 monoclonal antibody therapy (ipilimumab or tremelimumab), there is a risk of bowel perforation with IL-2 therapy; therefore, for these patients if they have a history of colitis or diarrhea during anti-CTLA4 monoclonal antibody therapy, they should have a formal evaluation by a gastroenterologist and a colonoscopy should be considered to demonstrate the absence of active bowel inflammation before initiating IL-2 therapy on this protocol * Life expectancy of greater than 3 months in the opinion of the investigator * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky \> 70%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within 1.5 x institutional upper limit of normal * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal * Creatinine within 1.5 x institutional upper limit of normal OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine level above institutional normal * Urine protein should be screened by urinalysis for urine protein creatinine ratio (UPCR); for UPCR \> 1, a 24-hour urine protein should be obtained and the level should be \< 500 mg * Patients on full-dose anticoagulants (e.g., warfarin) with prothrombin time (PT) international normalized ratio (INR) \> 1.5 are eligible provided that both of the following criteria are met: * The patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin * The patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) * Forced expiratory volume (FEV) 1 \> 2.0 liters or \> 75% of predicted for height and age (pulmonary function test \[PFTs\] are required for patients over 50 years old or with significant pulmonary or smoking history) * No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias, or unstable angina * Patients who are over 40 years old or have had previous myocardial infarction greater than 6 months prior to study entry or have significant cardiac family history (coronary artery disease \[CAD\] or serious arrhythmias) will be required to have a negative or low probability cardiac stress test (for example, thallium stress test, stress multi-gated acquisition scan \[MUGA\], stress echocardiography \[echo\], or exercise stress test) for cardiac ischemia within 8 weeks prior to registration * An echocardiogram should be performed at baseline in all patients; ejection fraction (EF) from baseline echocardiogram must be within the institutional limits of normal as determined by the reading cardiologist; if the baseline cardiac stress test incorporates an echocardiogram, then this will not need to be done again at baseline * No history of cerebrovascular accident or transient ischemic attacks within the past 6 months * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after completion of study therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Women should not be lactating and, if of childbearing age, should have a negative pregnancy test (beta-human chorionic gonadotropin \[b-HCG\] test; serum or urine, minimum sensitivity 25 IU/L or equivalent units of b-HCG) within two week of registration in the study * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Patients may not be receiving any other investigational agents * Patients with brain metastases should be excluded from this clinical trial except as noted above * Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, and patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the study * Serious or non-healing wound, ulcer, or bone fracture * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment * Patients with the following invasive procedures: * Major surgical procedures, open biopsy or significant traumatic injury within 28 days prior to day 1 therapy * Anticipation of need for major surgical procedures during the course of the study * Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 1 of therapy; central venous catheter placements are permitted to be completed 7 or more days prior to day 1 of therapy; however, peripherally inserted central catheter (peripherally inserted central catheter \[PICC\] or PIC line) may be placed at any time prior to or during therapy * Patients with clinically significant cardiovascular or cerebrovascular disease: * History of cerebrovascular accident or transient ischemic attack within past 6 months * Uncontrolled hypertension, defined as blood pressure \> 150/100 mm Hg or systolic blood pressure (BP) \> 180 mm Hg if diastolic blood pressure \< 90 mm Hg, on at least 2 repeated determinations on separate days within past 3 months * Myocardial infarction, coronary artery bypass graft (CABG) or unstable angina within the past 6 Months * New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past 6 months * Clinically significant peripheral vascular disease within past 6 months * Pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within past 6 months * History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy * PT INR \> 1.5 unless the patient is on full-dose warfarin * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible * Patients who have other current malignancies are not eligible; patients with other malignancies are eligible if they have been continuously disease free for \> 5 years prior to the time of randomization; patients with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia, or melanoma in situ are eligible; patients with a prior history of basal cell or squamous cell skin cancer are eligible; patients who have had multiple primary melanomas are eligible * Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids or steroid inhalers * If a patient had been taking steroids, at least 2 weeks must have passed since the last dose
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | The time from the date of randomization until date of progression, death, or recurrence, assessed up to 5 years | Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Until Death from any cause, up to 5 years | Estimated using the product-limit method of Kaplan and Meier. |
| Response Rate | Up to 5 years | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (RR) = CR + PR. |
| Progression-free Survival for Patients With High Vascular Endothelial Growth Factor (VEGF) Levels | Up to 5 years | Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median baseline measure for VEGF were used as the cut point for low vs high VEGF groups. |
| Progression-free Survival for Patients With Low VEGF Levels | Up to 5 years | Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median baseline measure for VEGF were used as the cut point for low vs high VEGF groups. |
| Count of Participants With Adverse Events | Up to 5 years | Count of the number of participants with grade 3 & 4 adverse events attributed to treatment agents. Events are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. |
Other
| Measure | Time frame | Description |
|---|---|---|
| 1-year Overall Survival Rate | Until Death from any cause, up to 1 year | Estimated using the product-limit method of Kaplan and Meier. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) Each course consisted of 2 cycles of HD IL2 at 600,000 IU/kg IV every 8 hours for up to 14 doses (1st cycle), followed by a period of 1 week rest and readmission for HD IL2 (2nd cycle). Ziv-aflibercept was given concurrently at 3 mg/kg IV every 2 weeks, starting 2 weeks prior to IL2 in course 1. In the absence of disease progression, maintenance ziv-aflibercept was given at 4 mg/kg every 2 weeks after completion of IL2 | 55 |
| Mono-therapy Arm (HD IL2 Alone) Patients received HD IL2 for a maximum of 3 courses (6 cycles) | 29 |
| Total | 84 |
Baseline characteristics
| Characteristic | Combination Arm (Ziv-Afilbercept+HD IL2) | Mono-therapy Arm (HD IL2 Alone) | Total |
|---|---|---|---|
| Age, Continuous | 55 years | 55 years | 55 years |
| Race/Ethnicity, Customized African American | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Caucasian | 54 Participants | 28 Participants | 82 Participants |
| Race/Ethnicity, Customized Hispanic | 0 Participants | 1 Participants | 1 Participants |
| Region of Enrollment United States | 55 Participants | 29 Participants | 84 Participants |
| Sex: Female, Male Female | 22 Participants | 11 Participants | 33 Participants |
| Sex: Female, Male Male | 33 Participants | 18 Participants | 51 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 37 / 55 | 20 / 29 |
| other Total, other adverse events | 55 / 55 | 29 / 29 |
| serious Total, serious adverse events | 28 / 55 | 7 / 29 |
Outcome results
Primary
Progression-free Survival
Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: The time from the date of randomization until date of progression, death, or recurrence, assessed up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) | Progression-free Survival | 6.9 months |
| Mono-therapy Arm (HD IL2 Alone) | Progression-free Survival | 2.3 months |
p-value: 0.002Log Rank
Secondary
Count of Participants With Adverse Events
Count of the number of participants with grade 3 & 4 adverse events attributed to treatment agents. Events are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Time frame: Up to 5 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Neutrophil count decreased | 2 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Confusion | 3 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Creatinine increased | 2 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Anemia | 2 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Leukocytosis | 1 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Lymphocyte count decreased | 41 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Fatigue | 5 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Platelet count decreased | 11 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Left ventricular systolic | 1 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Sinus tachycardia | 0 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Supraventricular tachycardia | 1 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Hypertension | 14 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Hypotension | 1 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Thromboembolic event | 2 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Fever and chills | 1 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Diarrhea | 0 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Oral mucositis | 0 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Nausea and vomiting | 2 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | LFTs increased | 13 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Lipase increased | 0 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Proteinuria | 6 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Urine output decreased | 8 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Dyspnea | 1 participants |
| Combination Arm (Ziv-Afilbercept+HD IL2) | Count of Participants With Adverse Events | Maculopapular rash | 1 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Nausea and vomiting | 2 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Hypotension | 4 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Confusion | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Dyspnea | 4 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Creatinine increased | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Lipase increased | 2 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Thromboembolic event | 1 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Anemia | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Fatigue | 3 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Leukocytosis | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | LFTs increased | 9 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Lymphocyte count decreased | 20 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Fever and chills | 1 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Neutrophil count decreased | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Urine output decreased | 7 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Platelet count decreased | 9 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Diarrhea | 1 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Left ventricular systolic | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Maculopapular rash | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Sinus tachycardia | 1 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Oral mucositis | 1 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Supraventricular tachycardia | 1 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Proteinuria | 0 participants |
| Mono-therapy Arm (HD IL2 Alone) | Count of Participants With Adverse Events | Hypertension | 0 participants |
Secondary
Overall Survival
Estimated using the product-limit method of Kaplan and Meier.
Time frame: Until Death from any cause, up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) | Overall Survival | 26.9 months |
| Mono-therapy Arm (HD IL2 Alone) | Overall Survival | 24.2 months |
p-value: 0.43Log Rank
Secondary
Progression-free Survival for Patients With High Vascular Endothelial Growth Factor (VEGF) Levels
Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median baseline measure for VEGF were used as the cut point for low vs high VEGF groups.
Time frame: Up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) | Progression-free Survival for Patients With High Vascular Endothelial Growth Factor (VEGF) Levels | 8.7 months |
| Mono-therapy Arm (HD IL2 Alone) | Progression-free Survival for Patients With High Vascular Endothelial Growth Factor (VEGF) Levels | 3.1 months |
p-value: 0.003Log Rank
Secondary
Progression-free Survival for Patients With Low VEGF Levels
Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median baseline measure for VEGF were used as the cut point for low vs high VEGF groups.
Time frame: Up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) | Progression-free Survival for Patients With Low VEGF Levels | 6.9 months |
| Mono-therapy Arm (HD IL2 Alone) | Progression-free Survival for Patients With Low VEGF Levels | 4.0 months |
p-value: 0.02Log Rank
Secondary
Response Rate
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (RR) = CR + PR.
Time frame: Up to 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) | Response Rate | 22 percentage of participants |
| Mono-therapy Arm (HD IL2 Alone) | Response Rate | 17 percentage of participants |
Other Pre-specified
1-year Overall Survival Rate
Estimated using the product-limit method of Kaplan and Meier.
Time frame: Until Death from any cause, up to 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Combination Arm (Ziv-Afilbercept+HD IL2) | 1-year Overall Survival Rate | 75.6 percentage of participants |
| Mono-therapy Arm (HD IL2 Alone) | 1-year Overall Survival Rate | 66.8 percentage of participants |